文献速递肝病

特应性药物性肝损伤的演变特征

The Evolving Profile of Idiosyncratic Drug-Induced Liver Injury.
PubMed 文献 · Clin Gastroenterol Hepatol · 2023-03-01

特应性药物性肝损伤(DILI)是少见但重要的肝病病因,新识别病因包括新冠疫苗、姜黄、绿茶提取物和免疫检查点抑制剂。DILI主要为排除性临床诊断,需评估更常见肝损伤原因并与可疑药物有合理时间关联。因果评估方面半自动修订电子因果评估方法(RECAM)有所进展,多种药物特异性HLA关联可辅助确认或排除DILI。多种预后模型可帮助识别死亡风险最高的5%-10%患者。停用可疑药物后80%患者完全恢复,10%-15%在6个月随访时实验室检查持续异常。住院DILI患者若国际标准化比值升高或精神状态改变,应考虑N-乙酰半胱氨酸治疗和紧急肝移植评估。部分伴中重度药物反应伴嗜酸性粒细胞增多和全身症状或肝活检自身免疫特征的患者可能从短期糖皮质激素获益,但需前瞻性研究确定最佳患者、剂量和疗程。

要点

  • DILI新识别病因包括新冠疫苗、姜黄、绿茶提取物和免疫检查点抑制剂。
  • 停用可疑药物后80%患者完全恢复,10%-15%在6个月随访时实验室检查持续异常。
  • 住院DILI患者若INR升高或精神状态改变,应考虑N-乙酰半胱氨酸治疗和紧急肝移植评估。

核心结论

  • DILI是少见但重要的肝病病因,新识别病因包括新冠疫苗、姜黄、绿茶提取物和免疫检查点抑制剂。
  • DILI主要为排除性临床诊断,需评估更常见肝损伤原因并与可疑药物有合理时间关联。
  • 因果评估方面RECAM有所进展,多种药物特异性HLA关联可辅助确认或排除DILI。
  • 多种预后模型可帮助识别死亡风险最高的5%-10%患者。
  • 停用可疑药物后80%患者完全恢复,10%-15%在6个月随访时实验室检查持续异常。

主要发现

  • 停用可疑药物后80%患者完全恢复,10%-15%在6个月随访时实验室检查持续异常。
  • 多种预后模型可帮助识别死亡风险最高的5%-10%患者。
  • 住院DILI患者若国际标准化比值升高或精神状态改变,应考虑N-乙酰半胱氨酸治疗和紧急肝移植评估。
  • 部分伴中重度药物反应伴嗜酸性粒细胞增多和全身症状或肝活检自身免疫特征的患者可能从短期糖皮质激素获益。
  • LiverTox网站收录超过1000种已批准药物和60种草药及膳食补充剂产品的肝毒性信息。

关键数值与推荐

  • 住院DILI患者若国际标准化比值升高或精神状态改变,应考虑N-乙酰半胱氨酸治疗和紧急肝移植评估。
  • 部分伴中重度药物反应伴嗜酸性粒细胞增多和全身症状或肝活检自身免疫特征的患者可能从短期糖皮质激素获益。
  • 需前瞻性研究确定糖皮质激素的最佳患者、剂量和疗程。

临床怎么用

  • DILI诊断需排除更常见肝损伤原因并确认与可疑药物的合理时间关联。
  • RECAM和药物特异性HLA关联可辅助DILI因果评估。
  • 预后模型可帮助识别死亡风险最高的5%-10%患者。
  • 住院DILI患者若INR升高或精神状态改变,应考虑N-乙酰半胱氨酸治疗和紧急肝移植评估。
  • 部分伴DRESS或肝活检自身免疫特征的患者可能从短期糖皮质激素获益,但需前瞻性研究确定最佳患者、剂量和疗程。

局限性

  • 需前瞻性研究确定糖皮质激素的最佳患者、剂量和疗程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Idiosyncratic drug-induced liver injury (DILI) is an infrequent but important cause of liver disease. Newly identified causes of DILI include the COVID vaccines, turmeric, green tea extract, and immune checkpoint inhibitors. DILI is largely a clinical diagnosis of exclusion that requires evaluation for more common causes of liver injury and a compatible temporal association with the suspect drug. Recent progress in DILI causality assessment includes the development of the semi-automated revised electronic causality assessment method (RECAM) instrument. In addition, several drug-specific HLA associations have been identified that can help with the confirmation or exclusion of DILI in individual patients. Various prognostic models can help identify the 5%-10% of patients at highest risk of death. Following suspect drug cessation, 80% of patients with DILI fully recover, whereas 10%-15% have persistently abnormal laboratory studies at 6 months of follow-up. Hospitalized patients with DILI with an elevated international normalized ratio or mental status changes should be considered for N-acetylcysteine therapy and urgent liver transplant evaluation. Selected patients with moderate to severe drug reaction with eosinophilia and systemic symptoms or autoimmune features on liver biopsy may benefit from short-term corticosteroids. However, prospective studies are needed to determine the optimal patients and dose and duration of steroids to use. LiverTox is a comprehensive, freely accessible Web site with important information regarding the hepatotoxicity profile of more than 1000 approved medications and 60 herbal and dietary supplement products. It is hoped that ongoing "omics" studies will lead to additional insight into DILI pathogenesis, improved diagnostic and prognostic biomarkers, and mechanism-based treatments.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Fontana RJ, Bjornsson ES, Reddy R, et al. The Evolving Profile of Idiosyncratic Drug-Induced Liver Injury. Clin Gastroenterol Hepatol. 2023. PMID: 36868489. doi:10.1016/j.cgh.2022.12.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。